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Treatment of juvenile rheumatoid arthritis
The systematic approach to pharmacologic treatment is typically to 
begin with the safest, simplest, and most conservative measures. It 
has been realized that the more rapidly inflammation is under control, 
the less likely it is that there will be permanent sequelae. Nonsteroidal 
anti-inflammatory drugs (NSAIDs) are the mainstay of initial treatment 
for inflammation. In addition, the slow-acting antirheumatic drugs 
(SAARDs) and disease-modifying antirheumatic drugs (DMARDs) have 
efficacy of anti-inflammatory action in children with chronic arthritis. 
New therapeutic modalities for inflammation, such as etanercept and 
infliximab, promise even further improvements in the risk/benefit 
ratio of treatment. It is not typically possible at the onset of the disease 
to predict which children will recover and which will go on to have 
unremitting disease with lingering disability or enter adulthood with 
serious functional impairment. Therefore, the initial therapeutic 
approach must be vigorous in all children.
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In addition, consultation with a physiatrist, psychiatrist, orthopedic 
surgeon, dentist, or nutritionist is often indicated. Moreover, 
regular ophthalmologic consultation is mandatory for JRA patients. 
Because this rheumatic disorder is characterized by chronic 
or recurrent inflammation of the joints and varying systemic 
manifestations, the child and his/her family should accept the need 
for long-term treatment and surveillance for effective management 
of the disease.
1. Nonsteroidal anti-inflammatory drugs (NSAIDs)
Most children with JRA are treated with one of the NSAIDs 
during the initial approach of therapy (Table 1). All of these drugs 
have antipyretic, analgesic, and anti-inflammatory actions, as 
well as a record of long-term safety. Most currently used NSAIDs 
inhibit the activity of cyclooxygenases 1 and 2 (COX-1 and COX-
Approach to management
The aims of juvenile rheumatic arthritis (JRA) treatment are 
to control pain; to preserve range of motion (ROM), muscle 
strength, and function; to manage systemic complications; and to 
facilitate normal nutrition, growth, and physical and psychological 
development. Thus, the general aim of treatment is remission rather 
than improvement. Although the major focus of medical therapy 
for JRA is on the arthritis, other extra-articular complications 
(e.g., uveitis, serositis, growth retardation, and osteopenia) re-
quire consideration
1). In general, the treatment program for this 
disease should be family-centered, community-based, and well 
coordinated. An ideal approach involves a multidisciplinary team 
that consists of a pediatric rheumatologist, nurse clinician, social 
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2, respectively). Therefore, these drugs have the potential to induce 
gastrointestinal (GI) irritation
2), although this side effect is unusual 
in children, and ranitidine may ameliorate it. New selective COX-
2 inhibitors are available, but have not generally been evaluated 
in children
3). Recent observations in clinical trials involving older 
adults have suggested an increased risk of cardiovascular events 
secondary to nonsteroidal anti-inflammatory drugs (NSAIDs), but 
there are no comparable studies in children. Consideration should 
be given to continuation of an NSAID for at least 3 to 6 months 
after all evidence of active disease has disappeared. One might 
also consider a different mode of withdrawal, such as decreasing 
administration to every 2 weeks for a period of time before 
discontinuation
1).
Naproxen has been shown effective in the management of 
joint inflammation in JRA at a dosage of 15 to 20 mg· kg
-1 · d
-1 
given with food, and it only requires administration twice daily. 
Naproxen is typically well tolerated, although mild epigastric 
discomfort has been occasionally encountered. In addition, 
cutaneous pseudoporphyria is a side effect of this drug, and is 
characterized by a bullous eruption on the face, hands, or other sun-
exposed areas, which often leaves an irregular, shallow scar on the 
affected individual.
Ibuprofen is a relatively mild anti-inflammatory agent and is 
typically well tolerated at a dosage of approximately 35 mg · kg
-1 · d
-1, 
divided into 3 or 4 doses given with food. The suspension that 
is commonly administered to children consists of both S and R 
enantiomers and is not absorbed as well as the tablets
6). It should 
therefore be given at a dosage of approximately 45 mg· kg
-1 · d
-1 
divided into 3 or 4 doses.
Tolmetin, which is given with food in 3 divided dosages totaling 
25-30 mg· kg
-1 · d
-1, is equally effective as an anti-inflammatory 
drug.
Diclofenac may be useful in children who are unable to tolerable 
other NSAIDs because of gastric side effects. This drug is typically 
prescribed in 3 doses per day; a slow-acting preparation is also 
available.
Sulindac is an inactive prodrug that is converted in vivo to 
active sulfide, and therefore offers little theoretical exposure to 
the GI mucosa. It has also been suggested that this prodrug is less 
nephrotoxic than other NSAIDs.
Celecoxib and, more recently, analogues of the COX-2 inhibitors 
have been introduced for treatment of arthritis in adults. These 
drugs are reputedly less likely to cause gastric irritation and peptic 
ulcer disease than traditional NSAIDs
3).
Indomethacin, typically at a dosage of 1-3 mg· kg
-1· d
-1 but 
up to a maximum of 125 mg· d
-1, is useful for treating fever and 
pericarditis associated with systemic disease. In many children, 
intermittent fever responds only to prednisone or indomethacin, 
the latter of which is a potent anti-inflammatory drug.
Piroxicam, which is only given once daily, may be particularly 
useful in older children and adolescents who are sometimes 
incompliant with taking prescribed medication.
Aspirin was previously the drug of choice in the initial manage-
ment of inflammation, but has more recently been replaced by 
the NSAIDs. The reasons for this switch are related more to 
convenience of administration and relative freedom from side 
effects than to superior efficacy. In addition, aspirin likely resulted 
in more frequent instances of transaminasemia than the newer 
NSAIDs. Aspirin is typically started at 75-90 mg· kg
-1 · d
-1 in 4 
doses given with food in order to minimize gastric irritation and 
to ensure therapeutic blood levels. It may be difficult to reach 
therapeutic levels in children with acute systemic disease, but care 
should be taken with increasing the dose beyond 130 mg· kg
-1 
because this often results in salicylism. Of note, awakening children 
at night to administer aspirin is unnecessary because the serum 
half-life of salicylate is prolonged once therapeutic levels have been 
achieved. In terms of side effects, aspirin and other NSAIDs are 
associated with interstitial nephritis and renal papillary necrosis
4).
2. Methotrexate
Methotrexate is considered the initial second-line agent for 
treating most children with chronic arthritis, because of its 
relatively rapid onset of action, efficacy, and acceptable toxicity. 
The advantages of this medication are its efficacy at a relatively low 
Table 1. Common NSAIDs and Coxibs
Drug  Brand Name
Salicylic Acids
Acetyllsalicylic acid
Acetic Acids
Diclofenac
Indomethacin
Sulindac
Ketorolac 
Tolmetin
Propionic Acids
Ibuprofen
Naproxen 
Fenoprofen
Ketoprofen
Oxicams
Piroxicam
Meloxicam
Nonacidic Compounds
Nabumetone
COX-2 Selective Inhibitors
Celecoxib 
Aspirin
Voltaren
Indocin
Clinoril
Toradol
Tolectin
Motrin, Advil
Naprosyn, Aleve
Nalfon
Orudis, Oruvail
Feldene
Mobic
Relafen
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dose, oral administration, once-a-week dosing, and apparent lack of 
oncogenicity and production of sterility
9). Most patients respond to 
this drug by 3 months, although a child may occasionally require a 
longer period of treatment. Methotrexate therapy should likely be 
continued for 1 year or longer after remission has been achieved. 
The principal toxicities of this drug are directed at the bone marrow, 
liver, and very rarely the lung. However, cirrhosis of the liver is not 
an expected toxic effect in children on a weekly therapy
10), although 
methotrexate-induced pneumonitis and effects on pulmonary 
function have been reported in children
11). Folic acid, given at 
1 mg· d
-1 during treatment with methotrexate, can reduce GI 
irritation and mucosal toxicity with no diminution in therapeutic 
effectiveness. Methotrexate is given as a single weekly dose on an 
empty stomach with clear liquids 45 minutes before breakfast; 
the minimum oral starting dose is 10 mg· m
-2 weekly. If a clinical 
response is inadequate or if oral administration is associated with 
nausea or vomiting, a trial of subcutaneous administration of the 
drug should be attempted. Methotrexate should be discontinued if 
no objective response is documented or if toxicity develops despite a 
reduction in dose.
3. Glucocorticoid drugs
Glucocorticoid medications are indicated for uncontrolled or 
life-threatening systemic disease, the treatment of chronic uveitis, 
and as an intra-articular agent. Systemic glucocorticoids should be 
administered to individuals with inflammation only with a well-
considered therapeutic plan and a clear set of clinical objectives. 
Although the use of glucocorticoid drugs alone for suppression of 
joint inflammation is to be discouraged, low-dose or alternate-day 
prednisone is of benefit to children with severe polyarthritis that is 
unresponsive to other therapeutic programs. Moreover, low-dose 
prednisone can be used as a “bridging” agent in the initial treatment 
of moderately to severely affected children who are started on 
other slower-acting, anti-inflammatory drugs at the same time
12). 
For severe uncontrolled systemic manifestations with marked 
disability, prednisone is often prescribed as a single daily morning 
dosage of 0.25-1.0 mg · kg
-1 · d
-1, or in divided doses for more severe 
disease. Prolonged use of systemic glucocorticoids has been shown 
to lead to iatrogenic Cushing’s syndrome, growth suppression, 
fractures, cataracts, and increased susceptibility to overwhelming 
infection. However, it often becomes difficult to reduce the dose of 
a glucocorticoid because of a child’s adaptation to chronic steroid 
excess
13). Moreover, steroid pseudorheumatism may complicate even 
slow withdrawal from the drug, particularly at lower dose levels.
Intravenous pulse glucocorticoid therapy offers an alternative 
approach to serious, unresponsive disease. The effect of this 
treatment is immediate and it is hoped that long-term toxicity 
is decreased
5). Methylprednisolone is the drug of choice for this 
therapy, often at a dose of 10-30 mg· kg
-1 per pulse. Established 
protocols of this technique consist of single pulses spaced 1 month 
apart, 3 pulses given sequentially on 3 d each month, or 3 pulses 
administered on alternate days each month. This therapy should 
always be given with cardiovascular monitoring of the patient 
during the infusion and for a time thereafter, paying careful 
attention to electrolyte and fluid balance, and to the potential for 
cardiac arrhythmia or acute hypertension.
The protocol for intra-articular glucocorticoid administration is 
changing, but at the present time it is clearly indicated in the mana-
gement of oligoarthritis that has not responded to an appropriate 
program of NSAIDs. Moreover, intra-articular glucocorticoid 
therapy should be considered in the management of polyarticular 
disease in which one or several target joints have not responded to 
NSAIDs or anti-inflammatory drugs. However, intra-articular 
injections should be given only a limited number of times per 
patient (3 times in a single joint during 1 year). Triamcinolone 
hexacetonide has been the drug of choice for large joints at a dose of 
20-40 mg. Younger children, in addition to those individuals who 
are undergoing injection of a hip joint or several joints, may require 
conscious sedation or light general anesthesia prior to the treatment.
4. Biologic response modifiers
Recent therapeutic approaches for children with unremitting 
inflammatory disease include soluble TNF-α receptor (TNFR) 
p75 fusion protein (etanercept) and recombinant monoclonal 
human immunoglobulin G (IgG) antibody to TNF-α (infliximab 
and adalimumab). A pivotal trial of adlimumab did prove its 
efficacy and ultimately resulted in the approval of the Food and 
Drug Administration (FDA). In addition, anti-interleukin (IL)-1 
and anti-IL-6 therapies also look very promising, particularly for 
systemic disease patients. The costimulation modifier abatacept was 
also shown to be effective and relatively well tolerated according to a 
short-term analysis of patients, which also resulted in FDA approval. 
Continued FDA procedures for monitoring safety will improve 
the ability to identify short- and long-term toxicities of these new 
agents
6).
Etanercept has become a standard therapy for arthritis that has 
not responded adequately to methotrexate. It is administered to 
patients at a minimum dose of 0.4 mg· kg
-1 subcutaneously twice 
a week with continuation of previous medications. However, this 
drug should not be started in any child with an infection or a 
history of recurrent infections. Furthermore, the risk of reactivation 
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disease as a result of this drug must be recognized. The long-term 
safety profile of etanercept indicated the drug can be maintained 
up to 8 years of continuous use. Exposure-adjusted rates of serious 
adverse effects (SAEs) were not shown to increase over time, and the 
most common new SAEs reported beyond 4 years of drug exposure 
were a flare or worsening of disease
7).
Adalimumab is a fully human, IgG, monoclonal anti-TNF 
antibody. The preliminary results of a multicenter, randomized, 
double-blinded, stratified study of this drug in polyarticular course 
JRA has previously been presented
8). Based on the data in this 
trial, the United States FDA approved adalimumab as treatment 
to reduce the signs and symptoms of moderately to severely active 
polyarticular JRA in patients 4 years of age and older, in February 
2008 (this was the first such approval for a biologic since 1999, 
when etanercept was approved)
9).
Abatacept is a fully human, soluble fusion protein composed 
of the extracellular domain of the cytotoxic T lymphocyte-
associated antigen cytotoxic T-lymphocyte antigen 4 (CTLA-
4) and the Fc component of IgG1, and selectively inhibits the 
costimulatory signal necessary for full T-cell activation
19). This drug 
was investigated in an international, multicenter, prospective study 
with a design similar to the ones used in the pivotal etanercept and 
adalimumab trials in JRA. This trial showed abatacept was effective 
and generally well tolerated by patients, which ultimately resulted 
in FDA approval for treatment of polyarticular JRA in March 
2008. Although it is difficult to compare results of separate trials, 
it appears that abatacept is as effective as anti-TNF agents, but its 
maximal effect may be achieved a few weeks later
10).
Infliximab has not been approved for use in children. How-
ever, infliximab (either 3 or 6 mg· kg
-1), in combination with 
methotrexate, has been shown to produce an important, rapid, 
and durable clinical effect in children with JRA at 1 year, but 
the primary efficacy endpoint of this study was not significantly 
different between the groups given infliximab or placebo at 14 
weeks of treatment. Also of note, the lower dose (3 mg· kg
-1) of 
infliximab was associated with a substantially higher risk of SAEs, 
infusion reactions, and the development of antibodies to infliximab, 
ANAs, and anti-dsDNA compared with the corresponding 
measures in those individuals given the 6 mg · kg
-1 dose. Thus, the 
use of infliximab in children warrants further investigation
11).
Recombinant interferon-γ has also been used experimentally. 
In one study, it was given to 10 children (6 systemic onset, 3 
polyarthritis, 1 oligoarthritis), of whom 8 showed significant 
improvement, and 7 entered remission
12).
Anakinra, which is a recombinant human IL-1 receptor 
antagonist (IL-1Ra), is currently undergoing therapeutic trials for 
treatment of chronic arthritis in children. There has been great 
interest in the role of IL-1 inhibition in the treatment of systemic 
JRA. Anakinra (1 mg·kg
-1) administered as a subcutaneous 
injection once daily was previously well tolerated in pediatric patients 
with JRA. Moreover, infection rates of these patients were low, 
and no clinically significant abnormalities in laboratory data were 
observed. However, efficacy results from the previous study were 
not conclusive because of the small sample size. Pharmacokinetic 
assessments indicated that a daily dosage of 1 mg · kg
-1 administered 
subcutaneously provided adequate exposure for the treatment of 
JRA. Safety data from this study were consistent with results from 
larger studies in adults and indicated that anakinra was safe and 
well tolerated in JRA patients
13).
Rilonacept, which is also called IL-1 trap, is a fusion protein 
composed of human cytokine receptor extracellular domains 
for both IL-1 type 1 receptor and the IL-1 accessory protein. 
Preliminary results of a phase II trial involving administration 
of this drug to systemic JRA patients have been presented and 
are published in abstract form
14); 2 different doses (2.2 and 4.4 
mg· kg
-1) were studied. Marked improvements in fever, rash, and 
active joint counts were noted at both doses.
Tocilizumab is a monoclonal anti-IL-6 receptor antibody that 
inhibits IL-6 activity
15). It has previously been reported to be 
effective in treating systemic JRA. Tocilizumab may also be useful 
for treatment of established amyloidosis.
Rituximab remains to be discussed in the context of JRA in the 
existing literature. That is, we were unable to find any published 
studies on rituximab for the treatment of JRA.
Thalidomide has been recommended for treatment of systemic 
onset arthritis
16).
5. Modes of advanced therapy
Slow-acting antirheumatic drugs (SAARDs) or disease-modi-
fying antirheumatic drugs (DMARDs) consist of cyclosporine, 
sulfasalazine, and antimalarials. Methotrexate has generally 
replaced the SAARDs in treating advanced cases of JRA. However, 
SAARDs remain to be considered for children who have an 
incomplete response to various combinations of an NSAID, 
methotrexate, and a TNF-α blocker.
Cyclosporine is given at an oral dosage of 3-5 mg· kg
-1 · d
-1 in 
2 divided doses exactly 12 hours apart. Blood pressure should be 
determined at home for 2 weeks during treatment with this drug and 
subsequently evaluated periodically with urinalyses and estimates 
of renal function. Of note, there may be a small long-term risk 
of developing lymphoma as a result of treatment. The role of this 
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likely critically important in treating reactive hemophagocytosis.   
Combined therapy of this drug with methotrexate has also been 
recommended in select children.
Hydroxchloroquine is a useful adjunctive agent for treating 
chronic arthritis in older children. The therapeutic effect of 
this drug is usually subtle and is rarely evident before 2 to 3 
months of therapy. If this drug causes no improvement in a 
patient after 6 months of treatment, it should be discontinued. 
Hydroxychloroquine is never used alone, but is instead added 
to an NSAID regimen, usually at a dosage of 5-6 mg· kg
-1 · d
-1. 
The medication should be taken with food because it can be a GI 
irritant. An ophthalmologic examination, including testing of color 
vision and visual fields, is usually performed before therapy is started 
and traditionally every 6 months thereafter. Hydroxychloroquine 
has not been recommended in children younger than 4 years of age, 
and sometimes in those younger than 7 years of age, because of the 
inability of young children to discern colors adequately for testing 
on grids or visual fields.
Sulfasalazine has been reported to have modest efficacy in some 
children with chronic arthritis, and it has the advantage of a more 
rapid onset of anti-inflammatory action than that which occurs 
with other SAARDs. This drug should not be used in children with 
known hypersensitivity to sulfa drugs or salicylate, impaired renal 
or hepatic function, or specific contraindications, such as porphyria 
or glucose-6-phosphate dehydrogenase deficiency. Moreover, severe 
side effects have been reported in children with systemic onset 
disease. Sulfasalazine is started at a dosage of 12.5 mg· kg
-1 · d
-1 
given with food, and this dose is gradually increased until a dosage 
of 50 mg· kg
-1 · d
-1 is reached. The benefits of the drug are usually 
apparent within 4 to 8 weeks after initiation of therapy.
6. Autologous stem cell transplantation
Bone marrow transplantation has been initiated as an experi-
mental treatment of severe autoimmune diseases including rheu-
matic diseases unresponsive to conventional therapy. Autologous 
stem cell transplantation (ASCT) is currently being evaluated, but 
only in a small number of children. This treatment approach is 
indicated only for children who are affected by severe active disease 
that fails to be controlled by conventional strategies, including anti-
TNF therapy.
In 1999, Wulffraat and co-workers first reported on ASCT 
in 4 Dutch children with longstanding and unresponsive JRA. 
All of these patients responded well and were disease-free during 
a follow-up period of 6-18 months. Furthermore, bone marrow 
reconstruction was found to be rapid. To date, approximately 30 
patients have undergone ASCT for JRA. Dramatic improvement 
was reported in 60-65% of the patients following the procedure. 
Wulffraat reported these results at the American College of 
Rheumatology 2000 conference.
Conclusion
In summary, there is no treatment algorithm uniformly agreed 
upon for the management of JRA. In general, NSAIDs can be 
used in all JRA types to control pain and diminish inflammation. 
Methotrexate at 15 mg· m
-2·week
-1 should be instituted upon 
confirmation of the diagnosis of the polyarticular course of JRA. A 
short course of oral prednisone (0.5-2 mg · kg
-1) may be required for 
particularly active forms of disease ). If the response to methotrexate 
is inadequate, a biologic agent should be added to the drug regimen. 
However, almost no evidence exists on the various biologic agents, 
such as etanercept, adalimumab, abatacept, anakinra, infliximab, 
rituximab, and tocilizumab. Moreover, because of the lack of sound 
long-term safety data, the existing evidence is insufficient to draw 
firm conclusions about the balance of the risks and benefits of using 
any biologic agent for treating JRA. Clinicians should be aware of 
this lack of evidence when considering biologics for patients with 
JRA.
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